Improved detection and precise relative quantification of the urinary cancer metabolite biomarkers - Creatine riboside, creatinine riboside, creatine and creatinine by UPLC-ESI-MS/MS: Application to the NCI-Maryland cohort population controls and lung cancer cases.
Biomarkers, Tumor
Chromatography, High Pressure Liquid
Creatine
/ analogs & derivatives
Creatinine
Humans
Lung Neoplasms
/ diagnosis
Maryland
National Cancer Institute (U.S.)
Neoplasm Recurrence, Local
Population Control
Reproducibility of Results
Ribonucleosides
Tandem Mass Spectrometry
United States
Creatine
Creatine ribose
Creatine riboside-(13)C,(15)N(2)
Creatinine
Creatinine riboside
UPLC-ESI-MS/MS
Urinary cancer biomarker
Journal
Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336
Informations de publication
Date de publication:
30 Nov 2020
30 Nov 2020
Historique:
received:
14
07
2020
revised:
11
08
2020
accepted:
12
08
2020
pubmed:
17
9
2020
medline:
22
6
2021
entrez:
16
9
2020
Statut:
ppublish
Résumé
Creatine riboside (CR) is a novel metabolite of cancer metabolism. It is a urinary diagnostic biomarker of lung and liver cancer risk and prognosis. The level of CR is highly positive correlated in tumor and urine indicating that it is derived from human lung and liver cancers. A precise and sensitive ultra-pressure liquid chromatography-tandem mass spectrometry (UPLC-ESI-MS/MS) method was developed and validated for simultaneous quantification of the noninvasive biomarker CR, along with creatinine riboside (CNR), and their precursors creatine and creatinine, utilizing the labeled internal standard creatine riboside-
Identifiants
pubmed: 32937240
pii: S0731-7085(20)31482-5
doi: 10.1016/j.jpba.2020.113596
pmc: PMC7756200
mid: NIHMS1654398
pii:
doi:
Substances chimiques
2-(2-(3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-1-methylcarbamimidamido)acetic acid
0
Biomarkers, Tumor
0
Ribonucleosides
0
Creatinine
AYI8EX34EU
Creatine
MU72812GK0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113596Subventions
Organisme : Intramural NIH HHS
ID : ZIA BC005708
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors disclose no potential conflict of interests.
Références
J Pharm Biomed Anal. 2013 Nov;85:288-94
pubmed: 23973759
Meat Sci. 2008 Aug;79(4):709-15
pubmed: 22063033
Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):978-86
pubmed: 27013655
Clin Biochem. 2010 Nov;43(16-17):1356-61
pubmed: 20709046
Clin Chem. 1998 Aug;44(8 Pt 1):1759-62
pubmed: 9702972
Anal Biochem. 2017 Jul 15;529:144-157
pubmed: 27840053
J Physiol. 2015 Sep 1;593(17):3959-71
pubmed: 26148133
Am J Physiol. 1999 Sep;277(3):R698-704
pubmed: 10484486
J Chromatogr A. 2005 Aug 26;1085(1):110-6
pubmed: 16106856
Cancer Causes Control. 2000 May;11(5):419-31
pubmed: 10877335
Toxicol Lett. 2011 Nov 30;207(2):173-81
pubmed: 21907771
Clin Cancer Res. 2017 Sep 1;23(17):5302-5310
pubmed: 28450405
Anal Chim Acta. 2017 Jun 15;972:28-37
pubmed: 28495093
Cancer Epidemiol Biomarkers Prev. 2019 Oct;28(10):1704-1711
pubmed: 31358519
Toxicology. 2011 Dec 18;290(2-3):241-8
pubmed: 22005293
Cancer Res. 2014 Jun 15;74(12):3259-70
pubmed: 24736543
J Chromatogr. 1990 Feb 23;525(2):265-75
pubmed: 2329158
Annu Rev Pharmacol Toxicol. 2012;52:37-56
pubmed: 21819238
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Dec 5;781(1-2):93-106
pubmed: 12450655
Spectrochim Acta A Mol Biomol Spectrosc. 2012 Jun 15;92:318-24
pubmed: 22446781
J Chromatogr. 1992 Nov 27;583(1):1-10
pubmed: 1484080
Clin Chim Acta. 2004 Jun;344(1-2):137-48
pubmed: 15149882
Mol Genet Metab. 2009 Apr;96(4):273-5
pubmed: 19188083
Anal Biochem. 2005 Jul 15;342(2):186-93
pubmed: 15927140
Biosens Bioelectron. 2016 Jan 15;75:347-51
pubmed: 26339931